RK
HUMA icon

Rather & Kittrell’s Humacyte HUMA Stock Holding History

Rather & Kittrell’s Portfolio HUMA Stock Details HUMA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$13.5K Hold
17,350
– – ﹤0.01% 108
2026
Q1 		$10.5K Hold
17,350
– – ﹤0.01% 113
2025
Q4 		$16.7K Hold
17,350
– – ﹤0.01% 106
2025
Q3 		$30.2K Hold
17,350
– – 0.01% 98
2025
Q2 		$36.3K Hold
17,350
– – 0.01% 90
2025
Q1 		$29.6K Hold
17,350
– – 0.01% 85
2024
Q4 		$87.6K Buy
+17,350
New +$85.8K 0.02% 81

Other funds holding HUMA

AP
Antipodes Partners Royal Exchange, Australia $5.46B AUM 26.64% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $38.9B AUM 28.51% 1-Year Est. Return
DKCM
Davidson Kempner Capital Management New York $8.42B AUM 61.81% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $529M AUM 337.4% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Rather & Kittrell's HUMA Position: Q2 2026 in Review

Rather & Kittrell held its Humacyte (HUMA) position steady in Q2 2026 at 17,350 shares worth $13.5K. The position accounts for ﹤0.01% of the portfolio, ranked #108.

Rather & Kittrell first reported a position in HUMA in Q4 2024 and has held it in 7 quarters since. The position peaked at $87.6K in Q4 2024. 162 funds tracked by Wall St. Rank hold HUMA as of Q2 2026.

  • Rather & Kittrell held 17,350 shares of Humacyte worth $13.5K as of Q2 2026.
  • Rather & Kittrell left its Humacyte share count unchanged in Q2 2026.
  • Humacyte made up ﹤0.01% of Rather & Kittrell's portfolio in Q2 2026, its #108 holding.
  • Rather & Kittrell first reported a position in Humacyte in Q4 2024 and has held it in 7 quarters since.
  • Rather & Kittrell's Humacyte position peaked at $87.6K in Q4 2024.
  • 162 funds tracked by Wall St. Rank held Humacyte as of Q2 2026.

Based on Rather & Kittrell's 13F filing for Q2 2026, filed 12 Aug 2026.